NOTE 4 - CAPITAL STOCK | Capitalization The authorized capital of the Company is 500,000,000 shares of capital stock, divided into 480,000,000 shares of common stock with a par value of $0.001 per share, and 20,000,000 shares of preferred stock with a par value of $0.001 per share. The Company reserved 10,000,000 shares of common stock for issuance under its 2016 Omnibus Equity Incentive Plan. The Company has issued 50,605,965 common shares and no preferred shares. During the three months ended March 31, 2020, the Company did not issue any shares of its common stock. Options A total of 10,000,000 options are issued and outstanding, of which 9,750,000 were vested at March 31, 2020. The remaining 250,000 will vest on November 20, 2020. On November 20, 2018, the Company granted 500,000 non-qualified stock options pursuant to its Equity Incentive Plan, to key outside consultants, with 50% vesting after one year and 50% vesting after two years. Each option is exercisable into one share of the Company’s common stock at a price of $0.06 per share, for a term of five years. The options had an estimated grant date fair value of $10,408. For the quarter ended March 31, 2020, $991 (Q1 2019 - $2,474) was included in consulting services expense, based on fair value estimates determined using the Black-Scholes option pricing model with an average risk-free rate of 2.88%, a weighted average life of 5 years, volatility of 195.37%, and dividend yield of 0%. At March 31, 2020, the options (including the 250,0000 unvested) had an intrinsic value of $15,000 (December 31, 2019: $7,000) based on the exercise price of $0.06 per option and a market price of $0.09 per share (December 31, 2019: $0.074). On February 14, 2017, the Company granted 9,500,000 non-qualified stock options pursuant to its Equity Incentive Plan, to key corporate officers and outside consultants, with 25% vesting immediately and a further 25% vesting every six months thereafter for eighteen months. Each option is exercisable into one share of the Company’s common stock at a price of $0.06 per share, equal to the closing price of the common stock on the grant date, for a term of five years. The options had an estimated grant date fair value of $536,750. The options were fully expensed by the end of the third quarter of 2018, based on fair value estimates determined using the Black-Scholes option pricing model. Therefore, no related expense was incurred in the current or comparative periods. At March 31, 2020, the options had an intrinsic value of $285,000 (December 31, 2019: $133,000) based on the exercise price of $0.06 per option and a market price of $0.09 per share (December 31, 2019: $0.074). Summary of option activity in the current three-month period and options outstanding at March 31, 2020: Years Life Remaining Years Options (Issued) Weighted Average Intrinsic Dec 31 Mar 31 Life Remaining Value Issued Vested 2019 2020 (Issued) Expiry Date (Issued) Issued February 14, 2017 9,500,000 9,500,000 2.13 1.88 February 14, 2022 $285,000 Issued November 20, 2018 500,000 250,000 3.89 3.64 November 20, 2023 $15,000 Balance December 31, 2019 10,000,000 9,750,000 2.21 Issued / Expired / Exercised - - Vested - - Balance March 31, 2020 10,000,000 9,750,000 1.96 $300,000 Warrants During the three months ended March 31, 2020 and March 31, 2019, no warrants to purchase shares of common stock were issued, exercised or expired. At March 31, 2020, warrants issued in 2015 had an intrinsic value of $233,524 (December 31, 2019: $180,147), based on the exercise price of $0.02 per warrant and a market price of $0.09 per share (December 31, 2019: $0.074). Summary of warrant activity in the current three-month period and warrants outstanding at March 31, 2020: Number of Exercise Weighted Weighted Expiry Date Intrinsic Balance December 31, 2019 3,336,060 $ 0.02 $ 0.02 0.89 November 19, 2020 $ 180,847 Issued / Expired / Exercised - Balance outstanding and exercisable at March 31, 2020 3,336,060 $ 0.02 $ 0.02 0.64 November 19, 2020 $ 233,524 |